Department of Health and Human Services July 10, 2024 – Federal Register Recent Federal Regulation Documents
Results 1 - 11 of 11
Agency Information Collection Activities: Submission for OMB Review; Comment Request
The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (PRA), federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, and to allow a second opportunity for public comment on the notice. Interested persons are invited to send comments regarding the burden estimate or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency's functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden.
Advisory Committee; Allergenic Products Advisory Committee; Termination; Removal From List of Standing Committees
The Food and Drug Administration (FDA or Agency) is announcing the termination of the Allergenic Products Advisory Committee, Center for Biologics Evaluation and Research. This document announces the reasons for termination and removes the Allergenic Products Advisory Committee from the Agency's list of standing advisory committees.
Agency Information Collection Activities: Proposed Collection; Comment Request
The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (PRA), Federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information (including each proposed extension or reinstatement of an existing collection of information) and to allow 60 days for public comment on the proposed action. Interested persons are invited to send comments regarding our burden estimates or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency's functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden.
Genetic Metabolic Diseases Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application 214927, for Arimoclomol
The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Genetic Metabolic Diseases Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.
Workshop To Consider Artificial Intelligence in Drug and Biological Product Development; Public Workshop
The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public workshop titled "Artificial Intelligence (AI) in Drug & Biological Product Development." Convened and supported by a cooperative agreement between FDA and the Clinical Trials Transformation Initiative (CTTI), the purpose of the public workshop is to bring drug developers and AI experts together to discuss guiding principles for the responsible use of AI in the development of safe and effective drugs and biological products. The workshop format will include presentations and panel discussions.
Reorganization of the Office of the Chief of Staff
CDC has modified its structure. This notice announces the reorganization of the Office of the Chief of Staff (OCS). OCS has retitled components and updated mission and function statements.
Reorganization of the Office of Financial Resources
CDC has modified its structure. This notice announces the reorganization of the Office of Financial Resources (OFR) and the CDC Immediate Office of the Director (IOD). OFR added a branch and a new office was established within the CDC IOD.
Agency Information Collection Activities: Proposed Collection; Comment Request; Withdrawal
On Tuesday, July 2, 2024, the Centers for Medicare & Medicaid Services (CMS) published a notice entitled, "Agency Information Collection Activities: Proposed Collection; Comment Request." The document invited public comments on four separate information collection requests notices specific to document identifiers: CMS-179, CMS-10536, CMS-R-153 and CMS-10326. Through the publication of this document, we are withdrawing each of the aforementioned notices.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
